Zolopa AR - Search Results

1

Gender inequality and HIV transmission: a global analysis.

Richardson ET, Collins SE, Kung T, Jones JH, Hoan Tram K, Boggiano VL, Bekker LG, Zolopa AR. Richardson ET, et al. Among authors: zolopa ar. J Int AIDS Soc. 2014 Jun 27;17(1):19035. doi: 10.7448/IAS.17.1.19035. eCollection 2014. J Int AIDS Soc. 2014. PMID: 24976436 Free PMC article.

2

Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations.

Richardson ET, Grant PM, Zolopa AR. Richardson ET, et al. Among authors: zolopa ar. Antiviral Res. 2014 Mar;103:88-93. doi: 10.1016/j.antiviral.2013.12.007. Epub 2013 Dec 25. Antiviral Res. 2014. PMID: 24374148 Free PMC article. Review.

3

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.

Collins SE, Grant PM, Uwinkindi F, Talbot A, Seruyange E, Slamowitz D, Mugeni A, Remera E, Niyonsenga SP, Nyirimigabo J, Uwizihiwe JP, Dongier P, Muhayimpundu R, Mazarati JB, Zolopa A, Nsanzimana S. Collins SE, et al. Open Forum Infect Dis. 2016 Jul 1;3(3):ofw141. doi: 10.1093/ofid/ofw141. eCollection 2016 Sep. Open Forum Infect Dis. 2016. PMID: 27704000 Free PMC article.

4

HIV drug resistance testing: an update for the clinician.

Rice HL, Zolopa AR. Rice HL, et al. Among authors: zolopa ar. AIDS Clin Care. 2001 Oct;13(10):89-91, 94-6, 100. AIDS Clin Care. 2001. PMID: 11590921 No abstract available.

5

Prevalence of measles antibodies in adults with HIV infection: possible risk factors of measles seronegativity.

Kemper CA, Zolopa AR, Hamilton JR, Fenstersheib M, Bhatia G, Deresinski SC. Kemper CA, et al. Among authors: zolopa ar. AIDS. 1992 Nov;6(11):1321-5. doi: 10.1097/00002030-199211000-00013. AIDS. 1992. PMID: 1472336

6

The use of resistance testing in the management of HIV-1-infected patients.

Grant PM, Zolopa AR. Grant PM, et al. Among authors: zolopa ar. Curr Opin HIV AIDS. 2009 Nov;4(6):474-80. doi: 10.1097/COH.0b013e328331c14f. Curr Opin HIV AIDS. 2009. PMID: 20048713 Review.

7

Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.

Gonzales MJ, Wu TD, Taylor J, Belitskaya I, Kantor R, Israelski D, Chou S, Zolopa AR, Fessel WJ, Shafer RW. Gonzales MJ, et al. Among authors: zolopa ar. AIDS. 2003 Apr 11;17(6):791-9. doi: 10.1097/00002030-200304110-00003. AIDS. 2003. PMID: 12660525 Free PMC article.

8

N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. Mitsuya Y, et al. Among authors: zolopa ar. AIDS Res Hum Retroviruses. 2006 Dec;22(12):1300-5. doi: 10.1089/aid.2006.22.1300. AIDS Res Hum Retroviruses. 2006. PMID: 17209774 Free PMC article.

9

Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose.

Grant P, Zolopa A. Grant P, et al. Curr HIV/AIDS Rep. 2009 May;6(2):63-7. doi: 10.1007/s11904-009-0010-3. Curr HIV/AIDS Rep. 2009. PMID: 19358776 Review.

10

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.

Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. Shulman N, et al. Among authors: zolopa ar. AIDS. 2001 Jun 15;15(9):1125-32. doi: 10.1097/00002030-200106150-00007. AIDS. 2001. PMID: 11416714

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112 results

Search Page